Workflow
Chemomab Therapeutics(CMMB)
icon
Search documents
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
ZACKS· 2024-06-27 17:01
Analysts have been steadily raising their estimates for Chemomab Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 33.3%. The upgrade of Chemomab Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging ...
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Newsfilter· 2024-06-18 11:00
TEL AVIV, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibroinflammatory diseases with high unmet need, today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The new study reinforces the extensive evidence showing the poten ...
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
GlobeNewswire News Room· 2024-06-06 11:00
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis— TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibroinflammatory d ...
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Newsfilter· 2024-06-06 11:00
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— The presentations cover a range of topics, from new preclinical studies further elucidating the roles of the novel soluble protein target CCL24 and Chemomab's CCL24-neutralizing antibody CM-101 in fibro-inflammatory liver disorders, to translational research supporting the clinical development of CM-101 for PSC, a ...
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
globenewswire.com· 2024-05-17 11:00
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro- inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver. Contacts: Media & Investors: Chemomab Therapeutics Barbara Lindheim Consult ...
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Newsfilter· 2024-05-17 11:00
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro- inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver. The presentations cover a range of topics, from new preclinical studies fur ...
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
Zacks Investment Research· 2024-05-10 14:56
After reaching an important support level, Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) could be a good stock pick from a technical perspective. CMMB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common cr ...
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Newsfilter· 2024-05-08 11:00
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq ...
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Newsfilter· 2024-04-24 11:00
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro- inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the earnings release has been issued are ...
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Globenewswire· 2024-04-24 11:00
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the earnings release has been issued are ...